Clinical Trial for Lung Cancer: 64 Real Stories

64 stories match lung cancer and clinical trial. 48 of them mention targeted therapy.

Leslie, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Leslie's Patient Story

Patient Info: Leslie, female | Stage IV

Biomarkers: ALK-positive

Metastatic Site: brain

Her brain metastases responded to targeted therapy without radiation, and she remains active and planning for the future while participating in a clinical trial.

GO2 Foundation
OutcomeResponding Well
Nina, who was diagnosed with Small Cell Lung CancerLung Cancer

Small Cell Lung Cancer: Nina's Patient Story

Patient Info: Nina, Female

Nina’s tumors began shrinking within weeks of starting trial immunotherapy, and she remained on the trial for 3 years without treatment side effects.

LUNGevity
OutcomeResponding Well
Carla, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Carla's Patient Story

Patient Info: Carla, Female | Stage IV

Metastatic Site: brain

After repeated resistance and a serious episode involving a brain lesion and extensive fluid around the lung, Carla recovered and was stable without new symptoms on her eighth line of treatment.

LUNGevity
OutcomeResponding Well
Bill, who was diagnosed with Stage III Lung CancerLung Cancer

Stage III KRAS Lung Cancer: Bill's Survivor Story

Patient Info: Bill Morris, Male | Stage III

Biomarkers: KRAS

After multimodal treatment, Bill had remained actively cancer-free for more than 3 years and used his experience to support other patients.

LUNGevity
OutcomeCancer-Free / NED
Mary, who was diagnosed with Lung CancerLung Cancer

Lung Cancer: Mary's Patient Story

Patient Info: Mary, Female

Mary received 4 cycles of chemotherapy, then radiotherapy and a clinical trial for lung cancer, while using MyChristie-MyHealth questionnaires to keep her clinical team updated between visits.

The Christie NHS
OutcomeCare Ongoing
Linnea, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: Linnea's Patient Story

Patient Info: Linnea Olson, Female, 40s | Stage IV

Biomarkers: ALK mutation / ALK-rearranged lung cancer

Metastatic Site: Lungs / intrapulmonary disease

Living long term with Stage IV ALK-positive NSCLC; ALK-targeted clinical trials controlled disease for years but were described as disease control rather than cure.

Massachusetts General Hospital
OutcomeLiving With Cancer
Jay, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Jay's Survivor Story

Patient Info: Jay Petri, Male | Stage IV

Biomarkers: ALK mutation / ALK-rearranged lung cancer

Metastatic Site: Not reported

Stage IV ALK-positive lung cancer treated through clinical trials at Mass General; he reported being cancer-free for nearly 1.5 years after going through 3 trials.

Massachusetts General Hospital
OutcomeCancer-Free / NED
Duane, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: Duane's Patient Story

Patient Info: Duane Steiner, Male, 50s | Stage IV

Biomarkers: ALK-positive / ALK gene mutation identified by molecular or genomic testing

Living more than 6 years with incurable Stage IV ALK-positive lung cancer, supported by targeted therapy, clinical-trial participation, Hope Lodge access, and periodic monitoring.

American Cancer Society
OutcomeLiving With Cancer
Lexi, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Lexi's Patient Story

Patient Info: Lexi, Female, Under 40 | Stage IV

Biomarkers: EGFR exon 20 mutation

Metastatic Site: Bone — left leg and hip

Living with Stage IV EGFR exon 20 metastatic NSCLC involving bone, after chemotherapy, targeted therapy, a drug trial, and surgery to remove the primary lung mass; latest disease-control status is not clearly stated.

Lung Cancer Research Foundation
OutcomeLiving With Cancer
Bill, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Bill's Patient Story

Patient Info: Bill, Male | Stage IV

Biomarkers: EGFR exon 21 mutation

Metastatic Site: Spine; brain; hips/bone

Stage IV EGFR exon 21 lung cancer improved in brain and spine on osimertinib, but later lung-mass growth led to clinical-trial treatment; Bill remained active in advocacy and felt positive about progress.

Lung Cancer Research Foundation
OutcomeSetback / Progression
Dann, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Dann's Patient Story

Patient Info: Dann Wonser, Male, 40s | Stage IV

Biomarkers: EGFR mutation; T790M mutation

Metastatic Site: Not reported

Dann Wonser passed away on June 30, 2024, 18 years after being diagnosed at age 49 with Stage IV EGFR/T790M-mutated lung cancer.

Lung Cancer Research Foundation
OutcomeIn Memory
Becky, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage III Lung Adenocarcinoma: Becky's Survivor Story

Patient Info: Becky Manning, Female, 40s | Stage III

After surgery, chemotherapy and 8 months of nivolumab on a clinical trial, Becky was no longer on active treatment, had no evidence of disease, felt well, and returned to MSK every 6 months for follow-up.

Memorial Sloan Kettering
OutcomeCancer-Free / NED
Lorie, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Lorie's Patient Story

Patient Info: Lorie Young | Stage IV

Biomarkers: NTRK1 fusion

After a couple of months on TL-118, Lorie’s CT scan showed a strong response, while longer-term disease control remained uncertain.

MD Anderson
OutcomeResponding Well
Anne, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Anne's Patient Story

Patient Info: Anne, Female | Stage IV

Biomarkers: EGFR-positive

Metastatic Site: spine; hips; lymph nodes; liver

Anne maintained a good quality of life for about 1 year on an oral EGFR-targeted medicine and later entered a clinical trial while continuing lung-cancer advocacy.

The Patient Story
OutcomeLiving With Cancer / Clinical Trial
Jake, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Jake's Patient Story

Patient Info: Jake, Male, Under 40 | Stage IV

Biomarkers: ALK-positive mutation

Metastatic Site: brain; lung; ankle bone

As of May 2026, Jake was 28 and had lived more than 13 years with Stage IV ALK-positive lung cancer, with ongoing treatment history including targeted therapy, surgeries, radiation, clinical-trial therapy, and recent chemotherapy.

The Patient Story
OutcomeLiving With Cancer
Kartik, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Kartik's Patient Story

Patient Info: Kartik, Male, Under 40 | Stage IV

Biomarkers: EML4/ALK mutation

Kartik was diagnosed with Stage IV ALK-rearranged lung cancer at age 28, continued working for several years through a targeted clinical trial, and died in 2015 at age 34.

GO2 Foundation
OutcomeIn Memory
Kelsey, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; later ALK mutation after progression

Metastatic Site: Bone — pelvis and spine/L5

Living with Stage IV lung cancer on a clinical trial after progression, with current treatment described as working and quality of life improved.

The Patient Story
OutcomeResponding Well
Natalie, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Natalie's Patient Story

Patient Info: Natalie, Female, Under 40 | Stage IV

Metastatic Site: Spine

Natalie was living with Stage IV NSCLC after a double lung transplant gave her new lung function, but cancer later appeared in the spine and required renewed chemotherapy and radiation.

The Patient Story
OutcomeLiving With Cancer
Maggie, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Maggie's Patient Story

Patient Info: Maggie, Female, 60s | Stage IV

Biomarkers: EGFR mutation; MET amplification resistance mutation; MET overexpression

Metastatic Site: Brain

Maggie initially reached no evidence of disease on EGFR-targeted therapy, but later had repeated progression, including MET-amplification resistance and MET overexpression, requiring SBRT, a clinical trial, chemotherapy, and later-line targeted treatment.

The Patient Story
OutcomeSetback / Progression
Phil, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ROS1 Lung Cancer: Phil's Patient Story

Patient Info: Phil, Male, 60s | Stage IV

Biomarkers: ROS1 mutation

Metastatic Site: Lymph nodes; other lung

Phil was living with incurable Stage IV ROS1-positive lung cancer. After initial chemotherapy, a ROS1-targeted pill worked for about 2 years, and he later continued on a Mass General clinical-trial treatment with follow-up every 3 months.

The Patient Story
OutcomeLiving With Cancer
Tina, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer treatment and follow-up story

Patient Info: Tina Powell, Female | Stage IV

As of January 2026, Tina was 3 years into Stage IV lung cancer, on a clinical trial at Memorial Sloan Kettering, and undergoing CT chest, CT pelvis, and brain MRI every 6 weeks.

YouTube (JA search)
OutcomeLiving With Cancer
Jennifer, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Jennifer's Patient Story

Patient Info: Jennifer, Female | Stage IV

Biomarkers: EGFR genomic mutation

Metastatic Site: Not reported

Jennifer is alive more than 5.5 years after a Stage IV adenocarcinoma diagnosis, continuing EGFR-targeted treatment and living with ongoing side effects and surveillance needs.

The Patient Story
OutcomeLiving With Cancer
Tina, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Tina's Patient Story

Patient Info: Tina Powell, Female | Stage IV

As of November 2025, Tina was living with Stage IV lung cancer after 27 chemotherapy rounds over 3 years and was receiving an antibody-drug conjugate in a clinical trial.

YouTube (AR search)
OutcomeLiving With Cancer